Garrido P, Paz-Ares L, Majem M, et al. - This study attempted to ascertain the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood-based on BEAMing technology to prognosticate disease progression in advanced non-small cell lung cancer (NSCLC) patients treated with first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Researchers enrolled stage IV NSCLC patients with locally confirmed EGFR-TKI sensitizing mutations (ex19del and/or L858R) in biopsy tissue who were candidates to receive first- or second-generation EGFR-TKI as first-line therapy. Among 110 patients, a total of 68 (61.8%) patients experienced a progression-free survival event. Using the highly sensitive BEAMing method, detection and quantification of EGFR mutations in circulating tumor DNA should greatly assist in optimizing treatment decisions for advanced NSCLC patients.